Ocular surface disease during dupilumab treatment in patients with atopic dermatitis, is it possible to prevent it?

J Eur Acad Dermatol Venereol. 2020 Jun;34(6):e255-e256. doi: 10.1111/jdv.16234. Epub 2020 Feb 13.

Authors

G Pistone¹, G Tilotta¹, R Gurreri¹, E Castelli¹, S Curiale¹, M R Bongiorno¹

Affiliation

¹ Section of Dermatology, Department of Health Promotion, Maternal-Infant, Internal Medicine and Specialization of Excellence "G. D'Alessandro" (PROMISE), University of Palermo, Palermo, Italy.

PMID: 31985084
DOI: 10.1111/jdv.16234

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized
Dermatitis, Atopic* / drug therapy
Eczema*
Humans
Interleukin-13

Substances

Antibodies, Monoclonal, Humanized
Interleukin-13
dupilumab